Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMAW) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 3,752 shares, a decrease of 84.7% from the June 30th total of 24,488 shares. Based on an average daily trading volume, of 15,476 shares, the short-interest ratio is presently 0.2 days.

Humacyte Stock Performance

Shares of NASDAQ:HUMAW traded up $0.00 during mid-day trading on Friday, hitting $0.01. 11,661 shares of the company traded hands, compared to its average volume of 17,359. The firm’s 50 day simple moving average is $0.03 and its 200 day simple moving average is $0.08. Humacyte has a 52-week low of $0.00 and a 52-week high of $0.58.

Humacyte Company Profile

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.